A RARE COMPLICATION OF BCG IMMUNOTHERAPY
Intravesical Bacillus Calmette-Guérin immunotherapy is an effective agent for superficial bladder carcinoma. The main adverse effect of this treatment is cystitis. Arthralgia and migratory arthritis occur only in 0.5% of patients. Reiter syndrome is a very rare complication that can occur after intravesical apply of Bacillus Calmette-Guérin Immunotherapy. We report the first Albanian patient who developed Reiter’s syndrome, following intravesical Bacillus Calmette-Guérin. Diagnose of Reiter’s Syndrome was clinically based, excluding every other reason that could have caused it. Treatment was made with non-steroid and steroid anti-inflammatory drugs, followed by a full recovery result. Even though Reiter's Syndrome is a rare, but significant complication of BCG immunotherapy, it’s important to identify it in time, in order we to offer an adequate treatment.
Barmoshe S, et al. (2004). Prognosis of T1G3 tumors: clinical factors. Eur Urol Suppl. 3:73–8.
Bernini L, et al (2013). Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature. Autoimmun Rev. 12(12):1150–1159
Brausi M, et al. (2014). Side effects of bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 65(1):69–76.
Decaestecker K, et al. (2015). Managing the adverse events of intravesical bacillus Calmette–Guérin therapy. Res Rep Urol. 7: 157–163.
Herr HW, et al (1989). Superficial bladder cancer treated with bacillus Calmette-Guérin: A multivariate analysis of factors affecting tumor progression. J Urol. 141:22–9
Hogarth M B, et al. (2000). Reiter’s syndrome following intravesical BCG Immunotherapy. Postgrad Med J 2000;76:791–795)
Keng Lim Ng a,b, et al (2017). Reiter’s syndrome postintravesical Bacillus Calmettee Gue´rin instillations.Asian Journal of Surgery Volume 40, Issue 2, Pages 163-165
Murata H, et al. (2004). Reiter’s syndrome following intravesical bacille bilié de Calmette–Guérin treatment for superficial bladder carcinoma: report of six cases. Mod Rheumatol 14:82–86
Pancaldi P, et al. (1993). Reiter’s syndrome after intravesical Bacillus Calmette-Guerin treatment for superficial bladder carcinoma. Br J Rheumatol ;32:1096–8.
Palnæs Hansen CP, et al. (1997). Epididymo-orchitis and Reiter’s disease. Two infrequent complications after intravesical Bacillus Calmette-Guerin therapy. Scand J Urol Nephrol; 31:317–18.
Spence. R. et al. (2006). Infection in the Cancer Patient a Practical Guide, Oxford University Press.
Sylvester RJ, et al. (2002). Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. Nov. 168(5):1964-70.
Selmi C, et al (2014). Gershwin ME; Diagnosis and classification of reactive arthritis. Autoimmun Rev. Apr-May 13(4-5):546-9.
Saporta L, et al.(1996). Reiter syndrome following intracavitory BCG administration. Scand J Urol Nephrol ;31:211–12.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (Creative Commons Attribution License 3.0 - CC BY 3.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
email@example.com, www.iseic.cz, ojs.journals.cz